Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FTRE
Upturn stock ratingUpturn stock rating

Fortrea Holdings Inc. (FTRE)

Upturn stock ratingUpturn stock rating
$5.32
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/20/2025: FTRE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $6.84

1 Year Target Price $6.84

Analysts Price Target For last 52 week
$6.84Target price
Low$3.97
Current$5.32
high$28.41

Analysis of Past Performance

Type Stock
Historic Profit -27.34%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 450.89M USD
Price to earnings Ratio -
1Y Target Price 6.84
Price to earnings Ratio -
1Y Target Price 6.84
Volume (30-day avg) 12
Beta 1.6
52 Weeks Range 3.97 - 28.41
Updated Date 06/30/2025
52 Weeks Range 3.97 - 28.41
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.39

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -29.43%
Operating Margin (TTM) -3.81%

Management Effectiveness

Return on Assets (TTM) -1.74%
Return on Equity (TTM) -61.58%

Valuation

Trailing PE -
Forward PE 29.41
Enterprise Value 1635138077
Price to Sales(TTM) 0.17
Enterprise Value 1635138077
Price to Sales(TTM) 0.17
Enterprise Value to Revenue 0.61
Enterprise Value to EBITDA 92.35
Shares Outstanding 90540304
Shares Floating 85353265
Shares Outstanding 90540304
Shares Floating 85353265
Percent Insiders 0.4
Percent Institutions 102.48

Analyst Ratings

Rating 4
Target Price 6.84
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold 10
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Fortrea Holdings Inc.

stock logo

Company Overview

overview logo History and Background

Fortrea Holdings Inc. was spun off from Labcorp (LH) in July 2023. It focuses on providing clinical development and commercialization solutions to the biopharmaceutical and healthcare industries.

business area logo Core Business Areas

  • Clinical Development: Provides comprehensive clinical trial management services, including Phase I-IV studies, data management, biostatistics, and medical writing.
  • Commercialization: Offers commercial strategy consulting, market access solutions, and medical affairs support to help biopharmaceutical companies bring their products to market.

leadership logo Leadership and Structure

Raymond F. Huml is the CEO of Fortrea. The company operates with a functional structure, organized around its key service areas.

Top Products and Market Share

overview logo Key Offerings

  • Clinical Trial Management: Comprehensive services for managing clinical trials from Phase I to Phase IV. Market share is evolving post-spinoff, estimated ~5-7% of CRO market. Competitors include IQVIA, ICON, and PPD (Thermo Fisher Scientific).
  • Commercialization Solutions: Strategic consulting and support for biopharmaceutical companies launching and marketing their products. Market share is smaller, highly fragmented. Competitors include Syneos Health, EVERSANA, and numerous specialized consultancies.

Market Dynamics

industry overview logo Industry Overview

The clinical research organization (CRO) market is experiencing growth driven by increasing R&D spending in the biopharmaceutical industry, the rising complexity of clinical trials, and the need for specialized expertise.

Positioning

Fortrea is a mid-sized CRO focused on providing integrated clinical development and commercialization solutions. Its competitive advantage lies in its ability to offer a comprehensive suite of services across the drug development lifecycle.

Total Addressable Market (TAM)

The global CRO market is estimated at approximately $75-85 billion. Fortrea is positioned to capture a share of this market by offering comprehensive, integrated solutions.

Upturn SWOT Analysis

Strengths

  • Comprehensive service offering
  • Strong industry expertise
  • Established relationships with biopharmaceutical companies
  • Experienced leadership team
  • Focus on both clinical and commercial phases

Weaknesses

  • Relatively new independent entity
  • Smaller scale compared to larger CROs like IQVIA
  • Brand recognition still developing
  • Integration challenges post-spinoff
  • High dependence on key client relationships

Opportunities

  • Increasing demand for CRO services
  • Growth in biopharmaceutical R&D spending
  • Expansion into emerging markets
  • Adoption of new technologies (e.g., AI) in clinical trials
  • Strategic partnerships and acquisitions

Threats

  • Intense competition in the CRO market
  • Economic downturn impacting R&D spending
  • Regulatory changes affecting clinical trials
  • Pricing pressures from biopharmaceutical companies
  • Loss of key personnel

Competitors and Market Share

competitor logo Key Competitors

  • IQVIA (IQV)
  • Thermo Fisher Scientific (TMO) (PPD is a part of this)
  • ICON (ICLR)
  • Syneos Health (SYNH)

Competitive Landscape

Fortrea is competing in a crowded market against larger, more established CROs. It aims to differentiate itself through its integrated service offerings and specialized expertise, but it needs to overcome the brand recognition of its competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is tied to Labcorp's previous clinical development segment. Future growth is expected to be driven by increasing demand for CRO services.

Future Projections: Analyst estimates for future growth will be available as the company releases its own forecasts and analyst coverage increases.

Recent Initiatives: Recent initiatives include establishing the company as an independent brand and focusing on strategic partnerships to expand its service offerings.

Summary

Fortrea, a recent spin-off from Labcorp, is a mid-sized CRO operating in a growing market. Its comprehensive services offer potential for growth, but it faces competition from established players. Its success depends on building its brand, executing its strategic initiatives, and navigating the evolving regulatory landscape and economical changes.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • Labcorp filings (prior to spin-off)
  • Industry reports
  • Analyst estimates

Disclaimers:

Data and analysis are based on available information and estimates, which are subject to change. This is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Fortrea Holdings Inc.

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 2023-07-03
Interim CEO, Chairman of the Board & Lead Independent Director Mr. Peter M. Neupert
Sector Healthcare
Industry Biotechnology
Full time employees 15000
Full time employees 15000

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.